FDA Brief

Warning letters Animal

FDA warning letter to

Synergy Animal Products, Inc.

High riskIssued Jul 16, 2025Posted Sep 2, 2025Center for Veterinary Medicine

Synergy Animal Products marketed unapproved animal drugs for dairy cows with inadequate directions and major manufacturing violations.

What happened

FDA inspected Synergy Animal Products’ Bethel, PA facility from September 5 through September 10, 2024, and then reviewed the company’s website. FDA found the company marketed products with claims to treat or prevent disease in dairy cows, making them unapproved new animal drugs, and that labeling lacked adequate directions for use. FDA also found no drug registration or listing and major current good manufacturing practice (CGMP) failures, including no quality unit, no testing, no written production records, and visibly dirty equipment.

What FDA found

  1. The company marketed Ex-Cell Countdown 7000, Natural Cow Herbal Support, Ex-Cell Somaticare, Superior Cow Cream, and Super Cow Udder Mint with claims that they treat or prevent disease in animals, so they are unapproved new animal drugs—drugs not FDA-approved for those uses.

    FD&C Act §§ 201(g)(1), 201(v), 512(a) [21 U.S.C. §§ 321(g)(1), 321(v), 360b(a)]
  2. The product labeling lacks adequate directions for use, including clear indications, routes, and frequency, in language laypersons can understand.

    FD&C Act § 502(f)(1) [21 U.S.C. § 352(f)(1)]; 21 CFR 201.5
  3. The company did not register its drug manufacturing establishment with FDA or list the animal drugs it makes.

    FD&C Act §§ 510(b), (j), 502(o) [21 U.S.C. §§ 360(b), (j), 352(o)]
  4. The company had no quality unit to approve or reject procedures, components, labeling, and drug products.

    21 CFR 211.22
  5. The company did not test incoming components for identity and did not test finished drug products for identity, strength, quality, and purity.

    21 CFR 211.84(d); 21 CFR 211.165(a)
  6. The company had no master production and control records or batch records and no written cleaning and maintenance procedures, and FDA observed visibly dirty equipment.

    21 CFR 211.186(a), 211.188, 211.67

What FDA wants

Within 15 working days of receipt, FDA tells the company to notify the agency in writing of specific corrective steps, how it will prevent recurrence, and supporting documents; if corrections are not complete, explain the delay and completion date. FDA also recommends engaging a qualified CGMP consultant to audit operations and help meet CGMP.

Who should pay attention

  • dairy farmers who buy udder-health products
  • veterinarians advising dairy producers
  • companies making or selling animal drugs for food-producing animals

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. AHC Products, Inc.

    AHC Products, Inc. was cited for manufacturing-rule violations and unapproved animal drugs, including AniPrin and Rot-B-Gone.

    High risk
  2. The Fish Aid

    FDA warned The Fish Aid it sells unapproved, unlisted antibiotics for aquarium fish and birds without veterinary oversight.

    High risk
  3. DK Hardware Supply

    FDA warns DK Hardware Supply over unapproved, unlisted aquarium-fish antibiotic drugs.

    High risk
  4. Boothwyn Pharmacy LLC

    FDA warns Boothwyn Pharmacy over unapproved compounded animal drugs and falsified endotoxin records.

    High risk